Abstract:Background and Aims Nonalcoholic fatty liver disease encompasses a spectrum of diseases ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), cirrhosis, and liver cancer. At present, how simple steatosis progresses to NASH remains obscure and effective pharmacological therapies are lacking. Hepatic expression of C-X-C motif chemokine ligand 1 (CXCL1), a key chemokine for neutrophil infiltration (a hallmark of NASH), is highly elevated in NASH patients but not in fatty livers in obese individuals or in high-fat diet (HFD)-fed mice. The aim of this study was to test whether overexpression of CXCL1 itself in the liver can induce NASH in HFD-fed mice and to test the therapeutic potential of IL-22 in this new NASH model. Approach and Results Overexpression ofCxcl1in the liver alone promotes steatosis-to-NASH progression in HFD-fed mice by inducing neutrophil infiltration, oxidative stress, and stress kinase (such as apoptosis signal-regulating kinase 1 and p38 mitogen-activated protein kinase) activation. Myeloid cell-specific deletion of the neutrophil cytosolic factor 1 (Ncf1)/p47(phox)gene, which encodes a component of the NADPH oxidase 2 complex that mediates neutrophil oxidative burst, markedly reduced CXCL1-induced NASH and stress kinase activation in HFD-fed mice. Treatment with interleukin (IL)-22, a cytokine with multiple targets, ameliorated CXCL1/HFD-induced NASH or methionine-choline deficient diet-induced NASH in mice. Mechanistically, IL-22 blocked hepatic oxidative stress and its associated stress kinases via the induction of metallothionein, one of the most potent antioxidant proteins. Moreover, although it does not target immune cells, IL-22 treatment attenuated the inflammatory functions of hepatocyte-derived, mitochondrial DNA-enriched extracellular vesicles, thereby suppressing liver inflammation in NASH. Conclusions Hepatic overexpression of CXCL1 is sufficient to drive steatosis-to-NASH progression in HFD-fed mice through neutrophil-derived reactive oxygen species and activation of stress kinases, which can be reversed by IL-22 treatment via the induction of metallothionein.

Interleukin-17 Exacerbates Hepatic Steatosis and Inflammation in Non-Alcoholic Fatty Liver Disease.

Interleukin-17A exacerbates high-fat diet-induced hepatic steatosis by inhibiting fatty acid β-oxidation.

Interaction Between Th17 Cells and Steatotic Hepatocytes in Nonalcoholic Fatty Liver Disease

Lamina Propria Interleukin 17 A Aggravates Natural Killer T-cell Activation in Autoimmune Hepatitis

Interleukin-17 Weakens the NAFLD/NASH Process by Facilitating Intestinal Barrier Restoration Depending on the Gut Microbiota

Il-17a Plays A Critical Role In The Pathogenesis Of Liver Fibrosis Through Hepatic Stellate Cell Activation

Anti-Il-17 Antibody Improves Hepatic Steatosis by Suppressing Interleukin-17-Related Fatty Acid Synthesis and Metabolism

Interleukin-22 Ameliorates Neutrophil-Driven Nonalcoholic Steatohepatitis Through Multiple Targets

Chronic Intermittent Hypoxia Promotes the Development of Experimental Non-Alcoholic Steatohepatitis by Modulating Treg/Th17 Differentiation

Contribution of endotoxin to Th17 bias in patients with non-alcoholic steatohepatitis.

A high-trans fat, high-carbohydrate, high-cholesterol, high-cholate diet-induced nonalcoholic steatohepatitis mouse model and its hepatic immune response

Hepatic IL22RA1 deficiency promotes hepatic steatosis by modulating oxysterol in the liver

Interleukin-17 Signaling in Inflammatory, Kupffer Cells, and Hepatic Stellate Cells Exacerbates Liver Fibrosis in Mice

Roles of Kupffer Cell Polarization and Hepatic Stellate Cell Activation in Hepatic Inflammation and Fibrosis in NAFLD

Interleukin-17-Producing CD4+ T Cells Promote Inflammatory Response and Foster Disease Progression in Hyperlipidemic Patients and Atherosclerotic Mice

Double-Negative T Cells Promote Liver Fibrosis Progression by Regulating Treg/Th17

1853-P: Neutrophils Play a Pivotal Role in Obesogenic Diet-Induced Nonalcoholic Steatohepatitis

Correlation between T-Lymphocyte Subsets, Regulatory T Cells, and Hepatic Fibrosis in Patients with Nonalcoholic Fatty Liver

IL‐17A‐mediated ERK1/2/p65 Signaling Pathway is Associated with Cell Apoptosis after Non‐alcoholic Steatohepatitis

Impaired Balance of T Helper 17/T Regulatory Cells in Carbon Tetrachloride-Induced Liver Fibrosis in Mice

Immune Imbalances in Non-Alcoholic Fatty Liver Disease: From General Biomarkers and Neutrophils to Interleukin-17 Axis Activation and New Therapeutic Targets